Esophageal cancer: a review and update
- PMID: 16836035
Esophageal cancer: a review and update
Abstract
Although significant advancements have been made in the treatment of esophageal cancer, this aggressive malignancy commonly presents as locally advanced disease with a poor prognosis. Despite improvements in the detection of premalignant pathology, newer preventative strategies, and the development of more effective combination therapies, the overall incidence of esophageal carcinomas has risen. A clear association has been established between the development of esophageal cancer and Helicobacter pylori infection, gastroesophageal reflux disease, smoking, and heavy alcohol use. However, the growing number of newly diagnosed esophageal adenocarcinomas, despite widespread treatments with proton pump inhibitors and the eradication of H. pylori, leaves the medical community searching for more answers. There is a potential link between esophageal adenocarcinoma and obesity. Common presenting symptoms of esophageal cancer are dysphagia, odynophagia, and progressive weight loss. The initial assessment for patients with these symptoms is made with double-contrast barium esophagraphy. Treatment modalities include surgery, chemotherapy, radiation therapy, or a combination of modalities. Prevention strategies include smoking and alcohol cessation.
Similar articles
-
Esophageal cancer: an update.Int J Surg. 2010;8(6):417-22. doi: 10.1016/j.ijsu.2010.06.011. Epub 2010 Jun 30. Int J Surg. 2010. PMID: 20601255 Review.
-
Esophageal cancer: an overview.Medsurg Nurs. 2000 Oct;9(5):248-54. Medsurg Nurs. 2000. PMID: 11904904 Review.
-
Palliation of malignant dysphagia in esophageal cancer: a literature-based review.J Support Oncol. 2006 Sep;4(8):365-73, 379. J Support Oncol. 2006. PMID: 17004508 Review.
-
Multimodality therapy of esophageal cancer: an update.Cancer J. 2000 Apr;6 Suppl 2:S177-81. Cancer J. 2000. PMID: 10803833 Review.
-
Risk factors for esophageal cancer development.Surg Oncol Clin N Am. 2009 Jul;18(3):469-85. doi: 10.1016/j.soc.2009.03.005. Surg Oncol Clin N Am. 2009. PMID: 19500737 Review.
Cited by
-
miR-1 suppresses the growth of esophageal squamous cell carcinoma in vivo and in vitro through the downregulation of MET, cyclin D1 and CDK4 expression.Int J Mol Med. 2016 Jul;38(1):113-22. doi: 10.3892/ijmm.2016.2619. Epub 2016 May 31. Int J Mol Med. 2016. PMID: 27247259 Free PMC article.
-
Genetic and molecular bases of esophageal Cancer among Iranians: an update.Diagn Pathol. 2019 Aug 31;14(1):97. doi: 10.1186/s13000-019-0875-4. Diagn Pathol. 2019. PMID: 31470870 Free PMC article. Review.
-
Role of microRNA-21 and effect on PTEN in Kazakh's esophageal squamous cell carcinoma.Mol Biol Rep. 2011 Jun;38(5):3253-60. doi: 10.1007/s11033-010-0480-9. Epub 2010 Nov 20. Mol Biol Rep. 2011. PMID: 21104017
-
Overexpression of human β-defensin 2 promotes growth and invasion during esophageal carcinogenesis.Oncotarget. 2014 Nov 30;5(22):11333-44. doi: 10.18632/oncotarget.2416. Oncotarget. 2014. PMID: 25226614 Free PMC article.
-
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.Oncotarget. 2015 Dec 29;6(42):44971-84. doi: 10.18632/oncotarget.6056. Oncotarget. 2015. PMID: 26462025 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical